Vertically integrated cannabis company Cansortium Inc. (CSE:TIUM) (OTCQB:CNTMF), operating under the FLUENT brand, launched the cannabis concentrate line, Hyer Kind. The Tampa-based multi-state operator notes that the new product is exclusively available at all FLUENT dispensaries across Florida.

Hyer Kind offers cured badder, crumble, and cured resin cartridges designed to support wellness routines and address the increasing interest in concentrates among medical marijuana patients in the Sunshine State.

"As FLUENT's first brand dedicated exclusively to concentrates, Hyer Kind marks a key milestone for us," stated Robert Beasley, CEO of Cansortium. "We are so proud to be associated with a quality brand like Hyer Kind and know consumers in Florida will be happy that this offering is now available in our stores. From the whole flower selection to the extraction methods, we're on a mission to set a new standard for concentrates by prioritizing flavor, quality, innovation and accessibility. It's our responsibility to meet patients where they are by expanding our offerings and providing diverse price points to ensure everyone has access to the products that suit their needs."

Read Also:

Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.

Hyer Kind products are developed to provide full-spectrum flavor derived from cannabis plants. The process involves selecting whole flowers and using hydrocarbon and solventless extraction techniques. Methods like live ice-water extraction are employed to maintain quality and potency for medical marijuana patients.

With plans to expand Hyer Kind into additional markets, including New York, its cured badder and resin cartridges (0.5g) are available exclusively to Florida patients for $50, with crumble priced at $45. FLUENT also plans to expand the brand's portfolio with additional concentrate options.

In October, the New York Cannabis Control Board approved the merger between Cansortium and RIV Capital. The merger, expected to close by the end of 2024, positions the combined company to take full advantage of covering 25% of the U.S. population with eight cultivation and processing facilities and 42 retail dispensaries.

Price Action

Cansortium shares closed Wednesday's market session 5.26% lower at $0.900 per share.

Read Next

• Canopy Growth, Aurora And Another Cannabis Giant Unveil Product Innovations, Here's What's New

Photo: Courtesy of fukume via Shutterstock,